[{"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-001", "question": "A 64-year-old man with metastatic hemangiopericytoma presents with refractory hypoglycemia (glucose 28 mg/dL) despite 20% dextrose infusion at 100 mL/hour. Labs show insulin <2 μIU/mL, C-peptide 0.1 ng/mL, IGF-2 850 ng/mL (normal 50-200), and IGF-2:IGF-1 ratio 12:1. Which immediate pharmacologic intervention is most likely to achieve euglycemia within 24 hours?", "options": ["Continuous hydrocortisone infusion 10 mg/hour", "Recombinant IGF-1 40 mg subcutaneously twice daily", "Diazoxide 300 mg orally three times daily", "Octreotide 200 μg subcutaneously three times daily", "Glucagon 2 mg intramuscularly every 4 hours"], "answer": "A", "answer_index": 0, "explanation": "High-dose glucocorticoids suppress aberrant IGF-2 production from the tumor, correcting hypoglycemia within hours. Recombinant IGF-1 (B) worsens the IGF-2:IGF-1 imbalance. Diazoxide (C) and octreotide (D) are ineffective in non-islet cell tumor hypoglycemia due to suppressed insulin. Glucagon (E) provides only transient effect and cannot sustain normoglycemia.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Endocrine", "abms_specialty": "Endocrine", "abms_source": "topics_mapped", "source_label_raw": "endocrinology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed123.jsonl", "pred": "A", "model_outputs": "Let me analyze this case systematically.\n\nClinical Presentation:\n- Severe refractory hypoglycemia (28 mg/dL)\n- Unresponsive to high-dose dextrose infusion\n- Metastatic hemangiopericytoma\n\nLaboratory Analysis:\n- Insulin <2 μIU/mL (LOW - rules out insulinoma)\n- C-peptide 0.1 ng/mL (LOW - confirms non-insulin mediated)\n- IGF-2 850 ng/mL (MARKEDLY ELEVATED - normal 50-200)\n- IGF-2:IGF-1 ratio 12:1 (ABNORMALLY HIGH)\n\nDiagnosis:\nThis is Non-Islet Cell Tumor Hypoglycemia (NICTH) caused by IGF-2 secretion from the hemangiopericytoma. The elevated IGF-2 with suppressed insulin/C-peptide is pathognomonic for this condition.\n\nMechanism:\nIGF-2 acts on insulin-like growth factor receptors to increase glucose uptake and suppress hepatic glucose production, causing hypoglycemia that is refractory to dextrose alone.\n\nTreatment Options Analysis:\n\nA. Hydrocortisone - Increases hepatic gluconeogenesis and antagonizes IGF-2 effects. This is a first-line treatment for NICTH and works within hours to days.\n\nB. Recombinant IGF-1 - Would worsen hypoglycemia by increasing glucose utilization.\n\nC. Diazoxide - Inhibits insulin secretion; ineffective here since insulin is already suppressed.\n\nD. Octreotide - Can help but primarily by inhibiting growth hormone; less effective than glucocorticoids for IGF-2-mediated hypoglycemia.\n\nE. Glucagon - Requires hepatic glycogen stores; ineffective in refractory hypoglycemia and doesn't address the underlying IGF-2 mechanism.\n\nBest Answer:\nContinuous hydrocortisone infusion is the most effective immediate pharmacologic intervention for IGF-2-mediated hypoglycemia, working by increasing hepatic glucose production and antagonizing IGF-2 effects. It can achieve euglycemia within 24 hours.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-002", "question": "A 42-year-old man with MEN1 syndrome (germline MEN1 c.628_631del) is found to have a 2.8 cm duodenal gastrinoma with 3 regional periduodenal lymph node metastases on Ga-68 DOTATATE PET/CT. Serum gastrin is 2,200 pg/mL with gastric pH <2. He has no pancreatic lesions. What is the optimal surgical management?", "options": ["A) Whipple pancreaticoduodenectomy with pylorus preservation", "B) Pancreas-preserving duodenectomy with regional lymphadenectomy", "C) Endoscopic submucosal dissection of the duodenal tumor", "D) Long-acting octreotide 30 mg monthly without surgery", "E) Tumor enucleation through duodenotomy only"], "answer": "B", "answer_index": 1, "explanation": "For large duodenal neuroendocrine tumors in MEN1, pancreas-preserving duodenectomy achieves oncologic clearance while preserving pancreatic function, which is critical as these patients inevitably develop pancreatic neuroendocrine tumors requiring future pancreatic surgery. Whipple procedure is excessively morbid for duodenal disease alone.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "abms_specialty": "Gastrointestinal", "abms_source": "target_topic", "source_label_raw": "Gastrointestinal", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nKey Clinical Features:\n- MEN1 syndrome with germline MEN1 mutation\n- 2.8 cm duodenal gastrinoma\n- 3 regional periduodenal lymph node metastases\n- High serum gastrin (2,200 pg/mL)\n- Gastric pH <2 (confirms severe acid hypersecretion)\n- No pancreatic lesions\n- Ga-68 DOTATATE PET/CT positive\n\nCritical Considerations for MEN1-Associated Gastrinomas:\n\n1. Duodenal vs Pancreatic Location: Duodenal gastrinomas in MEN1 are often multiple and small, but this one is 2.8 cm with nodal metastases - relatively aggressive.\n\n2. Lymph Node Involvement: The presence of 3 regional periduodenal lymph node metastases indicates regional spread and is a key factor in surgical decision-making.\n\n3. Surgical Options Analysis:\n   - Option A (Whipple): Extensive resection; typically reserved for large tumors or those with pancreatic involvement. Not standard for duodenal gastrinomas without pancreatic disease.\n   - Option B (Pancreas-preserving duodenectomy with lymphadenectomy): This addresses the duodenal tumor AND the regional lymph node metastases while preserving pancreatic tissue. This is the standard approach for duodenal gastrinomas with nodal involvement in MEN1.\n   - Option C (ESD): Inadequate for tumors >2 cm with lymph node metastases; high recurrence risk.\n   - Option D (Medical management alone): PPIs/octreotide control symptoms but don't address the malignant potential and nodal metastases.\n   - Option E (Enucleation): Inadequate for tumors with lymph node metastases; high recurrence risk.\n\n4. Current Guidelines: For MEN1-associated duodenal gastrinomas with regional lymph node metastases, pancreas-preserving duodenectomy with regional lymphadenectomy is the recommended approach to balance oncologic control with preservation of pancreatic function.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-003", "question": "A 59-year-old woman with rheumatoid arthritis on methotrexate develops progressive dyspnea and weight loss. HRCT demonstrates upper lobe-predominant pleural thickening, subpleural consolidation, and traction bronchiectasis with severe volume loss. Surgical lung biopsy shows dense subpleural fibrosis with prominent elastic fiber deposition and minimal inflammation, extending into the pleura. Which histopathologic finding most strongly differentiates this from usual interstitial pneumonia?", "options": ["Fibroblast foci within alveolar walls", "Honeycomb change with mucin-filled cysts", "Presence of intra-alveolar fibroblastic plugs", "Elastosis involving visceral pleura and subpleural parenchyma", "Patchy temporally heterogeneous fibrosis"], "answer": "D", "answer_index": 3, "explanation": "Pleuroparenchymal fibroelastosis (PPFE) is defined by characteristic elastosis of both pleura and subpleural parenchyma, which is absent in UIP. Fibroblast foci (A) and honeycomb change (B) are hallmark UIP features. Intra-alveolar fibroblastic plugs (C) suggest organizing pneumonia. Patchy heterogeneous fibrosis (E) is typical of UIP, whereas PPFE shows uniform elastotic fibrosis.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pulmonary", "abms_specialty": "Pulmonary", "abms_source": "topics_mapped", "source_label_raw": "pulmonology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-004", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed123.jsonl", "pred": "D", "model_outputs": "Let me analyze this case systematically.\n\nClinical Context:\n- 59-year-old woman with rheumatoid arthritis on methotrexate\n- Progressive dyspnea and weight loss\n- HRCT: upper lobe-predominant pleural thickening, subpleural consolidation, traction bronchiectasis, severe volume loss\n- Biopsy: dense subpleural fibrosis with prominent elastic fiber deposition, minimal inflammation, extending into pleura\n\nKey Finding:\nThe question emphasizes \"prominent elastic fiber deposition\" and asks what differentiates this from UIP (Usual Interstitial Pneumonia).\n\nAnalysis of Options:\n\nA. Fibroblast foci within alveolar walls\n- Present in both UIP and other fibrotic lung diseases\n- Not specific to differentiate\n\nB. Honeycomb change with mucin-filled cysts\n- Seen in UIP\n- Not the distinguishing feature here\n\nC. Presence of intra-alveolar fibroblastic plugs\n- Can be seen in organizing pneumonia and other conditions\n- Not the key differentiator\n\nD. Elastosis involving visceral pleura and subpleural parenchyma\n- This is the prominent elastic fiber deposition mentioned in the case\n- This is characteristic of rheumatoid lung disease (rheumatoid arthritis-associated interstitial lung disease)\n- Elastosis with pleural involvement is a distinctive feature that differentiates RA-ILD from UIP\n- UIP typically shows collagen deposition but not this prominent elastosis pattern\n\nE. Patchy temporally heterogeneous fibrosis\n- This is actually a hallmark of UIP\n- Would NOT differentiate from UIP\n\nConclusion:\nThe prominent elastic fiber deposition involving the visceral pleura and subpleural parenchyma is the key distinguishing feature of rheumatoid arthritis-associated ILD from UIP. This elastosis pattern is characteristic of RA-ILD.\n\nThe answer is (D)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-004", "question": "A 35-year-old woman with CFH p.Arg1215Gln mutation undergoes deceased donor kidney transplantation. On postoperative day 7, she develops rising creatinine (3.4 mg/dL), thrombocytopenia (45,000/μL), schistocytes, and hemolysis. Eculizumab 900 mg weekly was started preemptively on day 0. Platelets normalize by day 10 but creatinine continues to rise to 4.8 mg/dL. What is the next step?", "options": ["A) Increase eculizumab dose to 1,200 mg weekly", "B) Initiate daily plasma exchange with fresh frozen plasma", "C) Switch to ravulizumab 3,600 mg maintenance dose", "D) Measure eculizumab trough level and CH50 activity", "E) Proceed with transplant nephrectomy"], "answer": "D", "answer_index": 3, "explanation": "Breakthrough atypical HUS despite eculizumab requires therapeutic drug monitoring to distinguish underdosing from complement amplification via properdin or C5 gain-of-function mutation. Pharmacokinetic assessment guides therapy rather than empiric dose escalation or ineffective plasma exchange.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "abms_specialty": "Nephrology", "abms_source": "target_topic", "source_label_raw": "Nephrology", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "D", "model_outputs": "Let me work through this case systematically.\n\nKey Clinical Features:\n- CFH p.Arg1215Gln mutation (risk factor for aHUS/C3GN)\n- Post-transplant thrombotic microangiopathy (TMA): schistocytes, hemolysis, thrombocytopenia, rising creatinine\n- Started on eculizumab 900 mg weekly preemptively on day 0\n- Platelets normalized by day 10 (good response to complement inhibition)\n- BUT creatinine continues to rise (4.8 mg/dL)\n\nAnalysis:\n\nThe patient has complement-mediated TMA (post-transplant TMA with CFH mutation). The initial response (platelet recovery) suggests complement inhibition is working, but renal function continues to deteriorate.\n\nThe eculizumab dosing appears suboptimal:\n- Standard induction: 600 mg weekly × 4 weeks, then 900 mg at week 5, then 900 mg every 2 weeks\n- This patient received only 900 mg weekly starting day 0\n\nEvaluating Options:\n\nA) Increase dose to 1,200 mg weekly - Possible, but should verify adequacy of current dosing first\n\nB) Plasma exchange with FFP - This is for thrombotic thrombocytopenic purpura (TTP), not complement-mediated TMA. FFP could actually worsen disease by providing complement substrates.\n\nC) Switch to ravulizumab - Ravulizumab is a long-acting C5 inhibitor (IV infusion every 8 weeks after loading). This could be considered but seems premature without optimizing current therapy.\n\nD) Measure eculizumab trough level and CH50 activity - This is the most appropriate next step. The patient may have inadequate complement inhibition despite clinical improvement in platelets. Measuring drug levels and complement activity would:\n- Confirm adequate C5 inhibition (CH50 should be <10%)\n- Identify if dosing is insufficient\n- Guide therapeutic optimization\n\nE) Transplant nephrectomy - Too aggressive at this point; complement inhibition is partially working (platelet recovery)\n\nThe answer is D"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-005", "question": "A 28-year-old man is day +45 after matched unrelated donor allogeneic stem cell transplant for AML in CR1. He develops new hypertension (BP 165/100 mmHg), proteinuria (3.2 g/day), rising LDH (850 U/L), hemolysis, and thrombocytopenia. ADAMTS13 activity is 45%. Tacrolimus was stopped 14 days ago for rising creatinine. What is the appropriate therapy?", "options": ["A) Eculizumab 900 mg weekly IV", "B) High-dose methylprednisolone 1 g IV x3 days plus plasma exchange", "C) Rituximab 375 mg/m2 weekly for 4 doses", "D) Resume tacrolimus and target level 8-10 ng/mL", "E) Supportive care with aggressive blood pressure control only"], "answer": "A", "answer_index": 0, "explanation": "Transplant-associated thrombotic microangiopathy is mediated by complement activation independent of ADAMTS13; eculizumab blocks terminal complement and is the only effective therapy. Plasma exchange is ineffective; resuming calcineurin inhibitors worsens TMA.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "abms_specialty": "Hematology", "abms_source": "target_topic", "source_label_raw": "Hematology", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-006", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nClinical Presentation:\n- Day +45 post-allogeneic SCT\n- New hypertension, proteinuria (3.2 g/day), elevated LDH, hemolysis, thrombocytopenia\n- ADAMTS13 activity 45% (normal >60%)\n- Recently stopped tacrolimus\n\nDifferential Diagnosis:\nThis presentation is classic for thrombotic microangiopathy (TMA) post-transplant, specifically:\n1. Tacrolimus-associated TMA (most likely given recent use and stopping it)\n2. Atypical hemolytic uremic syndrome (aHUS) - would have very low/absent ADAMTS13\n3. Thrombotic thrombocytopenic purpura (TTP) - would have severely low ADAMTS13 (<10%)\n\nKey Diagnostic Point:\n- ADAMTS13 activity of 45% is mildly reduced but NOT severely deficient\n- This rules out TTP (which requires <10% activity)\n- This is consistent with tacrolimus-associated TMA or post-transplant TMA\n\nAnalysis of Options:\n\nA) Eculizumab - Used for complement-mediated aHUS; not first-line for tacrolimus-associated TMA\n\nB) High-dose methylprednisolone + plasma exchange - This is the standard treatment for post-transplant TMA/tacrolimus-associated TMA. Plasma exchange helps remove the offending agent and replace with normal plasma.\n\nC) Rituximab - Used for ADAMTS13 inhibitor-associated TTP; not appropriate here\n\nD) Resume tacrolimus - Contraindicated as tacrolimus is the likely culprit causing TMA\n\nE) Supportive care only - Insufficient; TMA requires active intervention\n\nBest Answer:\nGiven the clinical picture of post-transplant TMA with mildly reduced ADAMTS13 (not severely deficient), the appropriate therapy is high-dose corticosteroids plus plasma exchange, which is the standard of care for tacrolimus-associated TMA.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-006", "question": "A 14-year-old girl with chronic atypical neutrophilic dermatosis, lipodystrophy, and recurrent fevers (CANDLE syndrome) has persistent inflammatory lesions and fevers despite anakinra 100 mg daily and canakinumab 150 mg monthly. Genetic testing confirms PSMB8 c.224C>T mutation. What is the next therapy?", "options": ["A) High-dose prednisone 1 mg/kg/day", "B) Baricitinib 4 mg daily (JAK1/2 inhibitor)", "C) Tocilizumab 8 mg/kg IV monthly", "D) Thalidomide 100 mg nightly", "E) Allogeneic stem cell transplant"], "answer": "B", "answer_index": 1, "explanation": "CANDLE syndrome is a type I interferonopathy due to proteasome dysfunction; JAK inhibitors block downstream interferon signaling and are effective when IL-1 blockade fails. Baricitinib has shown efficacy in refractory cases. Anti-IL-6 and thalidomide are ineffective; transplant is experimental.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "abms_specialty": "Immunology", "abms_source": "target_topic", "source_label_raw": "Immunology", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-007", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "B", "model_outputs": "Looking at this case systematically:\n\nCANDLE Syndrome Background:\n- Autoinflammatory disorder caused by PSMB8 mutations (proteasome subunit)\n- Characterized by chronic inflammation, lipodystrophy, and recurrent fevers\n- IL-1 and IL-6 are key inflammatory mediators\n\nCurrent Treatment Status:\n- Patient is on anakinra (IL-1 receptor antagonist) 100 mg daily\n- Also on canakinumab (IL-1β monoclonal antibody) 150 mg monthly\n- Despite dual IL-1 pathway blockade, still has persistent symptoms\n- This indicates inadequate response to IL-1 targeted therapy alone\n\nAnalysis of Options:\n\nA) High-dose prednisone - Would provide temporary control but not ideal for chronic management and has significant side effects in a 14-year-old\n\nB) Baricitinib (JAK1/2 inhibitor) - JAK inhibitors have shown efficacy in autoinflammatory diseases by blocking multiple inflammatory pathways (IL-6, IFN-γ, and others). This addresses the broader inflammatory cascade beyond just IL-1\n\nC) Tocilizumab (IL-6 inhibitor) - While IL-6 is involved, the patient is already on potent IL-1 blockade; adding another single cytokine inhibitor is less likely to be effective\n\nD) Thalidomide - Not standard for CANDLE syndrome management\n\nE) Allogeneic stem cell transplant - Reserved for severe, refractory cases; premature at this stage\n\nRationale for B:\nJAK inhibitors are increasingly recognized as effective in autoinflammatory diseases, particularly when IL-1 pathway blockade alone is insufficient. They provide broader immunomodulation by inhibiting multiple inflammatory cytokine signaling pathways. Baricitinib has demonstrated efficacy in various autoinflammatory conditions and represents the next logical step in this patient's treatment escalation.\n\nThe answer is B"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-007", "question": "An 8-year-old boy presents with recurrent fevers, livedo racemosa, recurrent lacunar strokes, and vasculitic neuropathy. Laboratory studies show low IgM, elevated IgA, and negative ANCA. Genetic testing confirms biallelic loss-of-function mutations in ADA2. Which biologic therapy is most effective for this condition?", "options": ["A) High-dose systemic glucocorticoids", "B) Intravenous cyclophosphamide", "C) Etanercept", "D) Anakinra", "E) Rituximab"], "answer": "C", "answer_index": 2, "explanation": "DADA2 (Deficiency of Adenosine Deaminase 2) causes vasculitis due to loss of ADA2 enzyme function, leading to macrophage polarization defects and TNF-alpha overproduction. Etanercept, a TNF-alpha inhibitor, is highly effective and can induce remission. Cyclophosphamide and steroids are less effective. Anakinra has variable response, and rituximab is ineffective as the disease is not B-cell mediated.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Rheumatology/Musculoskeletal", "abms_specialty": "Rheumatology/Musculoskeletal", "abms_source": "topics_mapped", "source_label_raw": "rheumatology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-010", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed124.jsonl", "pred": "C", "model_outputs": "This question describes a clinical presentation consistent with Deficiency of Adenosine Deaminase 2 (DADA2), which is confirmed by the biallelic ADA2 mutations.\n\nKey clinical features that point to DADA2:\n- Recurrent fevers\n- Livedo racemosa (characteristic skin finding)\n- Recurrent lacunar strokes (small vessel vasculitis)\n- Vasculitic neuropathy\n- Immunoglobulin abnormalities (low IgM, elevated IgA)\n- Negative ANCA (distinguishes from ANCA-associated vasculitis)\n\nDADA2 is a monogenic autoinflammatory vasculitis caused by loss-of-function mutations in ADA2, leading to impaired adenosine deaminase 2 function and dysregulation of TNF-α signaling.\n\nPathophysiology: ADA2 deficiency leads to increased TNF-α production and dysregulated inflammation.\n\nTreatment approach: Since this is a TNF-α-mediated disease, TNF-α inhibitors are the most effective therapy. Multiple case reports and small series have demonstrated that TNF-α inhibitors (particularly etanercept and adalimumab) are highly effective in controlling the vasculitic manifestations, reducing fever, preventing strokes, and improving outcomes in DADA2 patients.\n\nWhile glucocorticoids and other immunosuppressants may provide temporary control, TNF-α inhibitors address the underlying pathophysiology and are the standard of care.\n\nEtanercept (a TNF receptor fusion protein) is a TNF-α inhibitor and represents the most effective biologic therapy for DADA2.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-008", "question": "A 38-year-old man from Vietnam with chronic mucocutaneous candidiasis is found to have STAT1 gain-of-function c.821T>C mutation. He presents with disseminated umbilicated papular skin lesions, hepatosplenomegaly, and fevers. Skin biopsy shows intracellular yeast forms with central septation. What is optimal therapy?", "options": ["A) Liposomal amphotericin B 5 mg/kg/day alone for 14 days", "B) Voriconazole 6 mg/kg IV q12h then 4 mg/kg maintenance", "C) Liposomal amphotericin B induction then itraconazole maintenance plus ruxolitinib 10 mg BID", "D) Caspofungin 70 mg loading then 50 mg daily", "E) Fluconazole 800 mg loading then 400 mg daily"], "answer": "C", "answer_index": 2, "explanation": "STAT1 GOF causes defective Th17 immunity leading to refractory dimorphic fungal infections. Talaromyces marneffei requires initial amphotericin induction followed by itraconazole maintenance. Adding JAK inhibition (ruxolitinib) reverses the underlying immunodeficiency and is essential for cure.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "abms_specialty": "Infectious Disease", "abms_source": "target_topic", "source_label_raw": "Infectious Disease", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-008", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "C", "model_outputs": "Let me analyze this case systematically.\n\nKey Clinical Features:\n- 38-year-old from Vietnam with chronic mucocutaneous candidiasis\n- STAT1 gain-of-function mutation\n- Disseminated umbilicated papular lesions\n- Hepatosplenomegaly and fevers\n- Skin biopsy: intracellular yeast with central septation\n\nDiagnosis:\nThe clinical presentation with umbilicated papules, hepatosplenomegaly, and yeast with central septation is consistent with histoplasmosis (not candidiasis, despite the patient's history). The central septation is characteristic of *Histoplasma capsulatum*.\n\nSTAT1 Gain-of-Function Mutation:\nThis causes increased IFN-γ signaling, leading to:\n- Impaired Th17 responses\n- Increased susceptibility to intracellular pathogens like histoplasmosis\n- Chronic mucocutaneous candidiasis\n- Disseminated fungal infections\n\nOptimal Treatment for Disseminated Histoplasmosis with STAT1 GOF:\n\n1. Antifungal therapy: Liposomal amphotericin B for induction (gold standard for disseminated histoplasmosis), followed by itraconazole maintenance\n\n2. Immunomodulation: JAK inhibitors (ruxolitinib) are crucial in STAT1 GOF mutations because:\n   - They reduce excessive IFN-γ signaling\n   - They restore Th17 responses\n   - They improve immune control of intracellular pathogens\n   - They are increasingly recognized as essential adjunctive therapy in STAT1 GOF-associated infections\n\nAnalysis of Options:\n- A: Amphotericin B alone is incomplete (no maintenance therapy, no immunomodulation)\n- B: Voriconazole monotherapy is suboptimal for disseminated histoplasmosis\n- C: Liposomal amphotericin B induction + itraconazole maintenance + ruxolitinib - This addresses both the fungal infection AND the underlying immunologic defect\n- D: Caspofungin is not ideal for histoplasmosis\n- E: Fluconazole is inadequate for disseminated disease\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-009", "question": "A 72-year-old woman with metastatic melanoma on combination ipilimumab/nivolumab develops six watery stools daily. Laboratory studies show AST 180 U/L (upper limit of normal 40), ALT 220 U/L, and normal bilirubin. Colonoscopy reveals ulcerative colitis-like changes. What is the next step in management?", "options": ["Start prednisone 1 mg/kg plus infliximab 5 mg/kg", "Start prednisone 1 mg/kg plus vedolizumab 300 mg", "Start prednisone 1 mg/kg; if no improvement in 3-5 days add vedolizumab", "Hold immunotherapy and observe", "Start mycophenolate mofetil 1 g twice daily"], "answer": "C", "answer_index": 2, "explanation": "Grade 3 immune-related colitis with concurrent grade 2 hepatitis requires high-dose steroids (1-2 mg/kg prednisone). Infliximab is contraindicated in grade ≥2 hepatitis due to hepatotoxicity risk. Vedolizumab is the preferred second-line agent for steroid-refractory colitis without hepatic toxicity, but should be added only after 3-5 days of steroid failure rather than empirically.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "abms_specialty": "Medical Oncology", "abms_source": "target_topic", "source_label_raw": "Medical Oncology", "source_quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "source_question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251225T234023630Z_kimi-k2-thinking_seed133", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251225T234023630Z_kimi-k2-thinking_seed133.jsonl", "pred": "C", "model_outputs": "This question involves immune checkpoint inhibitor (ICI)-induced colitis, a serious immune-related adverse event (irAE).\n\nKey clinical features:\n- Patient on ipilimumab/nivolumab (combination ICIs)\n- 6 watery stools daily (moderate-to-severe diarrhea)\n- Elevated transaminases (AST 180, ALT 220) suggesting hepatitis as concurrent irAE\n- Colonoscopy confirms ulcerative colitis-like changes\n\nManagement approach for ICI-induced colitis:\n\nSeverity assessment: 6 stools/day with colonoscopic confirmation = Grade 2-3 colitis (moderate-to-severe)\n\nStandard management algorithm:\n- Grade 1 (mild): Hold ICI, supportive care\n- Grade 2 (moderate): Hold ICI, start corticosteroids (prednisone 1 mg/kg)\n- Grade 3-4 (severe): Hold ICI, high-dose corticosteroids, consider anti-TNF agents\n\nRegarding anti-TNF agents (infliximab):\n- Traditionally used in IBD\n- However, anti-TNF agents can paradoxically worsen ICI-induced colitis and increase risk of secondary infections\n- NOT recommended as first-line for ICI-induced colitis\n\nRegarding vedolizumab:\n- Integrin antagonist (safer than anti-TNF in ICI setting)\n- Preferred agent if corticosteroids fail\n- Should be added if no improvement after 3-5 days of corticosteroids\n\nAnalysis of options:\n- A: Infliximab is contraindicated in ICI-induced colitis\n- B: Vedolizumab can be used but typically after steroid trial first\n- C: Correct approach - start corticosteroids, add vedolizumab if inadequate response in 3-5 days\n- D: Too conservative given Grade 2-3 colitis with colonoscopic confirmation\n- E: Mycophenolate is not standard first-line\n\nThe answer is C"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-010", "question": "A 42-year-old woman with lifelong idiopathic anaphylaxis, chronic urticaria, joint hypermobility, and baseline serum tryptase of 35 ng/mL is found to have heterozygous TPSAB1 copy number gain (α-tryptasemia). Symptoms persist despite high-dose cetirizine 40 mg daily and omalizumab 300 mg monthly. What is next therapy?", "options": ["A) Increase omalizumab to 600 mg monthly", "B) Prophylactic prednisone 10 mg daily", "C) Cromolyn sodium 200 mg QID", "D) Ketotifen 2 mg BID (mast cell stabilizer)", "E) Allergen immunotherapy based on skin testing"], "answer": "D", "answer_index": 3, "explanation": "Hereditary Alpha-Tryptasemia Syndrome causes constitutive mast cell activation; ketotifen stabilizes mast cell membranes and is effective when antihistamines fail. Omalizumab has variable efficacy; cromolyn is poorly absorbed systemically. Steroids are not prophylactic therapy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "abms_specialty": "Allergy/Immunology", "abms_source": "target_topic", "source_label_raw": "Allergy/Immunology", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-010", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "C", "model_outputs": "Let me work through this case systematically.\n\nKey Clinical Features:\n- 42-year-old woman with idiopathic anaphylaxis and chronic urticaria\n- Joint hypermobility (suggests possible connective tissue disorder)\n- Baseline serum tryptase 35 ng/mL (elevated; normal <11.4)\n- Heterozygous TPSAB1 copy number gain (α-tryptasemia)\n- Failed therapy: high-dose cetirizine 40 mg daily + omalizumab 300 mg monthly\n\nUnderstanding α-tryptasemia:\n- TPSAB1 copy number gain causes elevated baseline tryptase\n- Associated with mast cell activation syndrome (MCAS)\n- Patients have increased mast cell burden and reactivity\n- Often refractory to standard antihistamine/biologic therapy\n\nEvaluating Options:\n\nA) Increase omalizumab to 600 mg monthly\n- Already on omalizumab 300 mg with inadequate response\n- Omalizumab targets IgE; less effective in MCAS with normal IgE\n- Doubling dose unlikely to help if mechanism is mast cell activation\n\nB) Prophylactic prednisone 10 mg daily\n- Systemic corticosteroids suppress mast cell activation\n- However, chronic daily prednisone has significant side effects\n- Not first-line for MCAS management\n\nC) Cromolyn sodium 200 mg QID\n- Mast cell stabilizer that prevents degranulation\n- Excellent for MCAS and idiopathic anaphylaxis\n- Works locally and systemically\n- First-line agent for MCAS management\n- Addresses the underlying pathophysiology (mast cell activation)\n\nD) Ketotifen 2 mg BID\n- Mast cell stabilizer with H1 antagonist properties\n- Not available in US; limited evidence\n- Less established than cromolyn\n\nE) Allergen immunotherapy\n- Patient has idiopathic anaphylaxis (no identified allergen)\n- Not appropriate without specific allergen identification\n\nBest Answer:\nFor a patient with α-tryptasemia and MCAS refractory to antihistamines and omalizumab, mast cell stabilizers are the next logical step. Cromolyn sodium is the most established and effective mast cell stabilizer for this indication.\n\nThe answer is C"}]